RNA replicon for reprogramming somatic cells

US12291717B2 · kind B2 · utility

Assignees

• BIONTECH RNA PHARMACEUTICALS GMBH · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Marco Poleganov · Frankfurt, DE
• Mario Perkovic · Frankfurt, DE
• Ugur Sahin · Mainz, DE
• Tim Beissert · Groß-Gerau, DE

Key dates

• Filing date: Sep 11, 2018
• Grant date: May 6, 2025
• Expiry date: Aug 1, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/36143
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a reprogramming factor. Such RNA replicons are useful for expressing a reprogramming factor in a cell, in particular a somatic cell. Cells engineered to express such reprogramming factors are useful in cell transplantation therapies.